GlassScriptPhysician profile
Myra B Wilson
NPI 1992228753
$1,754.29
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $477 · 2022: $600 · 2023: $508 · 2024: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $365.56 | 2021-2024 | Mounjaro, Trulicity, Jardiance |
| Abbvie INC. | $295.26 | 2021-2023 | |
| Novo Nordisk INC | $201.12 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $145.22 | 2021-2024 | Xarelto |
| Xeris Pharmaceuticals, INC. | $117.66 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $108.83 | 2021-2023 | Breztri |
| Amgen INC. | $97.79 | 2021-2024 | Repatha, Otezla, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.92 | 2021-2024 | Xifaxan |
| Abbott Laboratories | $44.63 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.26 | 2022-2023 | Synjardy, Jardiance |
| Idorsia Pharmaceuticals US INC | $29.84 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $24.62 | 2021 | |
| Dexcom, INC. | $23.88 | 2022 | |
| Vanda Pharmaceuticals INC. | $23.22 | 2021 | |
| Amarin Pharma, INC. | $21.31 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $19.34 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $18.28 | 2022 | |
| Pfizer INC. | $16.24 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.42 | 2022 | |
| Vertical Pharmaceuticals, LLC | $13.59 | 2024 | Relexxii |
| Supernus Pharmaceuticals, INC. | $13.31 | 2023 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $13.07 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myra Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.